FLAURA2 Principal Investigator, Pasi A. Jänne, MD, PhD, discusses the final overall survival analysis from the phase 3 trial.
EGFR+ Non-Small Cell Lung Cancer
Osimertinib plus chemotherapy showed a “statistically significant and clinically meaningful improvement" in overall ...
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Dr. Liu discusses the implications of the accelerated approval and what the future may hold.
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
The approval is for adults who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.